Eisai Launches Leqembi in India, the Country's First Disease-Modifying Therapy for Early Alzheimer's
Japan-based Eisai has launched 'Leqembi' (lecanemab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). It is the first disease-modifying therapy in the country for early-stage Alzheimer's disease.
This launch addresses the rising dementia burden in India, which affected 8.8 million elderly individuals in 2023 and is projected to double by 2036.